Asia Pacific Dyspepsia Drug Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
Asia-Pacific Dyspepsia Drug Market By Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug Induced Dyspepsia, and Others), Treatment Type (Medication and Surgery), Drug Type (Branded and Generic), Prescription (Without Prescription Drugs and Prescription Drugs), Route of Administration (Oral and Injectable), Gender (Male and Female), End User (Hospitals, Clinics, Homecare settings, Specialty Clinics, Ambulatory Surgical Centers, Academic and Government Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030.
Asia-Pacific Dyspepsia Drug Market Analysis and Insights
The Asia-Pacific dyspepsia drug market is expected to grow in the forecast period due to the increasing prevalence of dyspepsia and the rising adoption of unhealthy lifestyles. The market is also influenced by the increase in the prevalence of metabolic disorders. However, the Asia-Pacific dyspepsia drug market is expected to be hampered by the possible side effects of the drugs used for dyspepsia and the increasing preference for natural and herbal remedies. The growing aging population and rise in drug approval are expected to act as opportunities for market growth. However, stringent regulations and a lack of awareness about dyspepsia among the population is expected to challenge the market growth.
Data Bridge Market Research analyzes that the Asia-Pacific dyspepsia drug market is expected to grow at a CAGR of 6.1% during the forecast period of 2023 to 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in Thousand, Volumes in Units, and Pricing in USD |
|
Segments Covered |
Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug Induced Dyspepsia, and Others), Treatment Type (Medication and Surgery), Drug Type (Branded and Generic), Prescription (Without Prescription Drugs and Prescription Drugs), Route of Administration (Oral and Injectable), Gender (Male and Female), End User (Hospitals, Clinics, Homecare settings, Specialty Clinics, Ambulatory Surgical Centers, Academic and Government Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) |
|
Countries Covered |
Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, New Zealand, Vietnam, Taiwan, and Rest of Asia-Pacific |
|
Market Players Covered |
Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others |
Market Definition
Dyspepsia, commonly known as indigestion, is the pain and discomfort experienced in the abdomen after eating. It is usually a sign of an underlying condition like GERD (gastroesophageal reflux disease), gallbladder, and ulcer disease. Treatment for dyspepsia depends on the cause and severity. Treating an underlying condition or changing a person's medication will reduce dyspepsia. Dyspepsia is divided into 2 main categories: "organic" and "functional dyspepsia" (FD). Organic causes of dyspepsia are peptic ulcer, gastroesophageal reflux disease, gastric or esophageal cancer, pancreatic or biliary disorders, intolerance to food or drugs, and other infectious or systemic diseases. Functional dyspepsia (dis-PEP-see-uh) is a term for recurring symptoms of an upset stomach that have no obvious cause. Functional dyspepsia is also called non ulcer dyspepsia.
Asia-Pacific Dyspepsia Drug Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
- Increasing prevalence of dyspepsia
Dyspepsia, commonly known as indigestion, is a gastrointestinal disorder that affects millions of people in Asia-Pacific. It is a condition that causes discomfort, pain, and a feeling of fullness or bloating in the upper abdomen. Dyspepsia can be caused by a variety of factors such as eating too quickly, consuming spicy or fatty foods, or as a side effect of medication.
The increasing prevalence of dyspepsia is one of the key driving factors for the growth of the dyspepsia drug market. The rising incidence of dyspepsia can be attributed to several factors such as changes in lifestyle, dietary habits, and an aging population. As people age, they are more susceptible to digestive problems, including dyspepsia. With the growing number of older adults, there is a higher demand for dyspepsia drugs.
In addition, different digestive diseases like irritable bowel syndrome, gastroparesis, gastritis, and peptic ulcer disease also cause dyspepsia, due to the increasing prevalence of the mentioned disease. Thus the growing prevalence of dyspepsia and other digestive disorders causing dyspepsia is expected to act as the driver for the market’s growth. The use of dyspepsia drugs for relieving the symptoms of dyspepsia and treating the dyspepsia has the potential to improve patient outcomes and reduce the burden of dyspepsia. Thus, the increasing prevalence of dyspepsia is driving the demand for dyspepsia drugs worldwide to increase the incidence and prevalence of the dyspepsia among population.
- Rise in the adoption of unhealthy lifestyle
In recent years, there has been a rise in the adoption of unhealthy lifestyles, which has contributed to an increase in the prevalence of dyspepsia. Unhealthy lifestyle choices such as a diet high in processed foods, lack of exercise, and excessive alcohol consumption can all contribute to dyspepsia.
As a result, there has been a corresponding increase in the demand for dyspepsia drugs, as people seek relief from their symptoms. The dyspepsia drug market has responded to this demand with a variety of medications, including proton pump inhibitors, H2 receptor antagonists, and antacids.
The rise in the adoption of unhealthy lifestyles can be attributed to several factors, including changes in dietary habits, increasing stress levels, and a sedentary lifestyle. Modern life is often characterized by long working hours, high levels of stress, and easy access to fast food and other unhealthy options. These factors can contribute to dyspepsia and other related conditions such as gastroesophageal reflux disease (GERD).
In conclusion, dyspepsia is a common condition that can be caused by a variety of factors, including unhealthy lifestyle choices. The rise in the adoption of unhealthy lifestyles has contributed to an increase in the prevalence of dyspepsia, and the demand for effective dyspepsia drugs has correspondingly increased which is expected to act as a driver for the growth of the market.
OPPORTUNITY
- Growing aging population
The number of people who are 65 and older is expected to reach 1.5 billion by the year 2050, according to estimates, which shows that the world's population is rapidly aging and growing older. People have a higher risk of developing chronic health conditions as they get older. This includes digestive disorders such as dyspepsia, which can occur as a result of aging.
There is a significant opportunity for the expansion of the dyspepsia drug market presented by the growing and aging population. Because more and more people are having problems with their digestive systems, there is a growing need for effective treatments that can reduce the severity of their symptoms and enhance their overall quality of life.
In addition, the treatment of dyspepsia may need to be tailored specifically to the requirements of an aging population. It is possible for older people to have multiple chronic conditions and to be taking multiple medications at the same time, both of which can increase the likelihood of negative drug interactions and side effects. As a result, there is a demand for dyspepsia medications that are both risk-free and effective when administered to older adults. And with aging people also lose their physical and immunity strength which leads to causing an increasing prevalence of several gastro-related diseases including dyspepsia.
Hence increase in the aging population causing dyspepsia and its symptoms and the people's preference for preventive healthcare is expected to act as an opportunity for the growth of the dyspepsia drug market.
RESTRAINT/CHALLENGE
- Lack of awareness about dyspepsia among the population
The shortage of skills is already impacting the nation, with an increasing number of people being forced to wait more than six months for their dental treatments. There is a shortage of skilled professionals in the field of Dyspepsia Drug in emerging or developing countries due to technical advancements, basic infrastructure, and several other factors.
The lack of skilled professionals is partly due to the rigorous education and training required to become a dental professional as well as the competitive job market. Moreover, skilled dentists need more formally-trained, licensed dental assistants to help maintain and increase access to oral healthcare to operate and execute advanced technological systems such as dyspepsia drug systems.
The emerging countries lack skilled professionals who cannot operate the new technologies effectively. This might create a challenge in the market for new technologies to emerge as these countries are delaying the onset of technologically driven advancements in the market.
Recent Developments
- In April 2023, Sanofi announced that it had completed the acquisition of Provention Bio, Inc. This acquisition has helped the company in the expansion of its business in general medicine.
- In July 2022, ANI Pharmaceuticals, Inc. announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.
Asia-Pacific Dyspepsia Drug Market Segmentation
The Asia-Pacific dyspepsia drug market is segmented into type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Non-Ulcer Dyspepsia
- Organic Dyspepsia
- Drug Induced Dyspepsia
- Others
Based on type, Asia-Pacific dyspepsia drug market is segmented into organic dyspepsia, non-ulcer dyspepsia, drug induced dyspepsia, and others.
Treatment Type
- Medication
- Surgery
Based on treatment type, Asia-Pacific dyspepsia drug market is segmented into medication and surgery.
Drug Type
- Branded
- Generic
Based on drug type Asia-Pacific dyspepsia drug market is segmented into generic, and branded.
Prescription
- Without Prescription Drugs
- Prescription Drugs
Based on prescription, Asia-Pacific dyspepsia drug market is segmented into without prescription drugs and prescription drugs.
Route of Administration
- Oral
- Injectable
Based on the route of administration, Asia-Pacific dyspepsia drug market is segmented into oral, and injectable.
Gender
- Male
- Female
Based on gender, Asia-Pacific dyspepsia drug market is segmented into male and female.
End User
- Hospitals
- Clinics
- Homecare Settings
- Specialty Clinics
- Ambulatory Centers
- Academic and Government Research Institutes
- Others
Based on end user, Asia-Pacific dyspepsia drug market is segmented into hospitals, clinics, homecare settings, specialty clinics, ambulatory surgical centers, academic and government research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
Based on the distribution channel, Asia-Pacific dyspepsia drug market is segmented into direct tenders and retail sales.
Asia-Pacific Dyspepsia Drug Market Regional Analysis/Insights
The Asia-Pacific dyspepsia drug market is analyzed, and market size insights and trends are provided based on type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel.
The countries covered in this market report are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, New Zealand, Vietnam, Taiwan, and Rest of Asia-Pacific.
Japan is expected to dominate the Asia-Pacific dyspepsia drug market due to a rise in the number of product approval in the country.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Dyspepsia Drug Market Share Analysis
The Asia-Pacific dyspepsia drug market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the market.
Some of the major market players operating in the market are Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END-USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA
7 INDUSTRY INSIGHTS:
8 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, REGULATION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS
9.2 RESTRAINTS
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES
9.3 OPPORTUNITIES
9.3.1 GROWING AGING POPULATION
9.3.2 RISE IN THE DRUG APPROVAL
9.4 CHALLENGES
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION
9.4.2 STRINGENT REGULATIONS
10 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE
10.1 OVERVIEW
10.2 NON-ULCER DYSPEPSIA
10.3 ORGANIC DYSPEPSIA
10.4 DRUG INDUCED DYSPEPSIA
10.5 OTHERS
11 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 DRUGS
11.2.1.1 ANTACIDS
11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S)
11.2.1.1.1.1 OMEPRAZOLE
11.2.1.1.1.2 LANSOPRAZOLE
11.2.1.1.1.3 ESOMEPRAZOLE
11.2.1.1.1.4 OTHERS
11.2.1.1.2 H2 BLOCKERS
11.2.1.1.2.1 CIMETIDINE
11.2.1.1.2.2 FAMOTIDINE
11.2.1.1.2.3 NIZATIDINE
11.2.1.1.2.4 RANITIDINE
11.2.1.1.2.5 OTHERS
11.2.1.2 GASTRIC PROKINETIC GENDERNTS
11.2.1.2.1 MOSAPRIDE CITRATE
11.2.1.2.2 METOCLOPRAMIDE
11.2.1.2.3 CISAPRIDE
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE
11.2.1.2.5 DOMPERIDONE
11.2.1.2.6 OTHERS
11.2.1.3 ANTIBIOTICS
11.2.1.3.1 REFAXIMIN
11.2.1.3.2 AMOXICILLIN
11.2.1.3.3 CLARITHROMYCIN
11.2.1.3.4 METRONIDAZOLE
11.2.1.3.5 LEVOFLOXACIN
11.2.1.3.6 TETRACYCLINE
11.2.1.3.7 OTHERS
11.2.1.4 OTHERS
11.2.2 NON- DRUGS
11.2.2.1 PROBIOTICS
11.2.2.1.1 LACTOBACILLUS
11.2.2.1.2 BIFIDOBACTERIUM
11.2.2.1.3 BACILLUS
11.2.2.1.4 STREPTOCOCCUS
11.2.2.1.5 OTHERS
11.2.2.2 PREBIOTICS
11.3 SURGERY
12 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERIC
12.3 BRANDED
13 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION
13.1 OVERVIEW
13.2 WITHOUT PRESCRIPTION DRUGS
13.3 PRESCRIPTION DRUGS
14 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS
14.2.2 CAPSULES
14.3 INJECTABLE
15 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER
15.1 OVERVIEW
15.2 FEMALE
15.2.1 30-50 YEARS
15.2.2 MORE THAN 50 YEARS
15.2.3 AGE LESS THAN 30
15.3 MALE
15.3.1 30-50 YEARS
15.3.2 MORE THAN 50 YEARS
15.3.3 AGE LESS THAN 30
16 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.2.1 TYPE
16.2.1.1 PUBLIC
16.2.1.2 PRIVATE
16.2.2 TIER
16.2.2.1 TIER 3
16.2.2.2 TIER 2
16.2.2.3 TEIR 1
16.3 CLINICS
16.4 HOMECARE SETTINGS
16.5 SPECIALTY CLINICS
16.6 AMBULATORY CENTERS
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
16.8 OTHERS
17 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 RETAIL SALES
17.2.1 REATIL PHARMACY
17.2.2 HOSPITAL PHARMACY
17.2.3 ONLINE PHARMACY
17.3 DIRECT TENDER
18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY REGION
18.1 ASIA-PACIFIC
18.1.1 JAPAN
18.1.2 CHINA
18.1.3 SOUTH KOREA
18.1.4 INDIA
18.1.5 AUSTRALIA
18.1.6 NEW ZEALAND
18.1.7 SINGAPORE
18.1.8 THAILAND
18.1.9 INDONESIA
18.1.10 MALAYSIA
18.1.11 PHILIPPINES
18.1.12 VIETNAM
18.1.13 TAIWAN
18.1.14 REST OF ASIA-PACIFIC
19 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20 SWOT ANALYSIS
21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS
21.1 SANOFI
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENT
21.2 LUPIN
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 MANKIND PHARMA
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 ASTRAZENECA
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENT
21.5 BAYER AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENT
21.6 ABBOTT
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ANI PHARMACEUTICALS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTERISK LABORATORIES (I) PVT. LTD
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENT
21.1 CADILA PHARMACEUTICALS
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 COMPANY SHARE ANALYSIS
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENT
21.11 HANMI PHARM. CO., LTD.
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENT
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 OTSUKA PHARMACEUTICAL CO., LTD.
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 PERRIGO COMPANY PLC
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 PRESTIGE CONSUMER HEALTHCARE, INC.
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENT
21.16 PROCTER & GAMBLE
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENT
21.17 RECKITT BENCKISER.
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 REDHILL BIOPHARMA LTD
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SALIX PHARMACEUTICALS OR ITS AFFILIATES (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENT
21.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 WOODWARD PHARMA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 ZERIA PHARMACEUTICAL CO., LTD.
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
List of Table
TABLE 1 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 55 ASIA-PACIFIC H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030, (USD THOUSANDS )
TABLE 56 ASIA-PACIFIC H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 57 ASIA-PACIFIC GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 59 ASIA-PACIFIC ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 61 ASIA-PACIFIC NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 ASIA-PACIFIC PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 ASIA-PACIFIC PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 64 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 66 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 67 ASIA-PACIFIC ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 68 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 69 ASIA-PACIFIC FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 70 ASIA-PACIFIC MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 71 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 72 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 73 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 74 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 75 ASIA-PACIFIC RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 76 JAPAN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 JAPAN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 JAPAN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 JAPAN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 JAPAN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 JAPAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 JAPAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 83 JAPAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 84 JAPAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 JAPAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 86 JAPAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 87 JAPAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 JAPAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 89 JAPAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 90 JAPAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 91 JAPAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 92 JAPAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 93 JAPAN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 JAPAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 JAPAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 96 JAPAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 97 JAPAN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 JAPAN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 99 JAPAN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 100 JAPAN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 101 JAPAN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 102 JAPAN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 103 JAPAN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 104 JAPAN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 105 JAPAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 106 JAPAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 107 JAPAN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 108 JAPAN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 109 .CHINA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 110 CHINA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 CHINA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 CHINA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 CHINA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 CHINA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 CHINA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 116 CHINA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 117 CHINA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 CHINA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 119 CHINA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 120 CHINA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 121 CHINA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 122 CHINA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 123 CHINA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 CHINA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 125 CHINA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 126 CHINA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 127 CHINA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 128 CHINA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 129 CHINA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 130 CHINA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 CHINA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 132 CHINA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 133 CHINA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 134 CHINA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 135 CHINA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 136 CHINA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 137 CHINA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 138 CHINA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 CHINA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 140 CHINA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 141 CHINA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 142 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 143 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 SOUTH KOREA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 SOUTH KOREA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 146 SOUTH KOREA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 147 SOUTH KOREA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 SOUTH KOREA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 149 SOUTH KOREA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 150 SOUTH KOREA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 SOUTH KOREA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 152 SOUTH KOREA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 153 SOUTH KOREA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 154 SOUTH KOREA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 155 SOUTH KOREA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 156 SOUTH KOREA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 SOUTH KOREA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 158 SOUTH KOREA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 159 SOUTH KOREA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 SOUTH KOREA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 SOUTH KOREA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 162 SOUTH KOREA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 163 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 165 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 166 SOUTH KOREA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 167 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 168 SOUTH KOREA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 169 SOUTH KOREA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 170 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 171 SOUTH KOREA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 SOUTH KOREA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 173 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 174 SOUTH KOREA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 175 INDIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 INDIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 INDIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 INDIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 179 INDIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 INDIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 INDIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 182 INDIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 183 INDIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 184 INDIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 185 INDIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 186 INDIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 187 INDIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 188 INDIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 189 INDIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 INDIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 191 INDIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 192 INDIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 INDIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 INDIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 195 INDIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 196 INDIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 INDIA BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 198 INDIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 199 INDIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 200 INDIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 201 INDIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 202 INDIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 203 INDIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 204 INDIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 205 INDIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 206 INDIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 207 INDIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 208 INDIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 209 AUSTRALIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 210 AUSTRALIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 211 AUSTRALIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 AUSTRALIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 AUSTRALIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 AUSTRALIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 AUSTRALIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 216 AUSTRALIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 217 AUSTRALIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 218 AUSTRALIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 219 AUSTRALIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 220 AUSTRALIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 AUSTRALIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 222 AUSTRALIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 223 AUSTRALIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 224 AUSTRALIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 225 AUSTRALIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 226 AUSTRALIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 227 AUSTRALIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 228 AUSTRALIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 229 AUSTRALIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 230 AUSTRALIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 AUSTRALIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 232 AUSTRALIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 233 AUSTRALIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 234 AUSTRALIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 235 AUSTRALIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 236 AUSTRALIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 237 AUSTRALIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 238 AUSTRALIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 239 AUSTRALIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 240 AUSTRALIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 241 AUSTRALIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 242 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 243 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 244 NEW ZEALAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 NEW ZEALAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 NEW ZEALAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 NEW ZEALAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 248 NEW ZEALAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 249 NEW ZEALAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 250 NEW ZEALAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 251 NEW ZEALAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 252 NEW ZEALAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 253 NEW ZEALAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 254 NEW ZEALAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 255 NEW ZEALAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 256 NEW ZEALAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 257 NEW ZEALAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 258 NEW ZEALAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 259 NEW ZEALAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 260 NEW ZEALAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 261 NEW ZEALAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 262 NEW ZEALAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 263 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 265 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 266 NEW ZEALAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 267 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 268 NEW ZEALAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 269 NEW ZEALAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 270 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 271 NEW ZEALAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 272 NEW ZEALAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 273 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 274 NEW ZEALAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 275 SINGAPORE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 SINGAPORE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 SINGAPORE MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 SINGAPORE DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 279 SINGAPORE ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 280 SINGAPORE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 281 SINGAPORE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 282 SINGAPORE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 283 SINGAPORE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 284 SINGAPORE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 285 SINGAPORE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 286 SINGAPORE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 287 SINGAPORE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 288 SINGAPORE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 289 SINGAPORE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 290 SINGAPORE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 291 SINGAPORE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 292 SINGAPORE NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 293 SINGAPORE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 SINGAPORE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 295 SINGAPORE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 296 SINGAPORE DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 297 SINGAPORE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 298 SINGAPORE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 299 SINGAPORE ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 300 SINGAPORE DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 301 SINGAPORE FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 302 SINGAPORE MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 303 SINGAPORE DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 304 SINGAPORE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 305 SINGAPORE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 306 SINGAPORE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 307 SINGAPORE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 308 THAILAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 309 THAILAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 310 THAILAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 311 THAILAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 312 THAILAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 313 THAILAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 314 THAILAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 315 THAILAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 316 THAILAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 317 THAILAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 318 THAILAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 319 THAILAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 320 THAILAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 321 THAILAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 322 THAILAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 323 THAILAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 324 THAILAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 325 THAILAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 326 THAILAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 327 THAILAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 328 THAILAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 329 THAILAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 330 THAILAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 331 THAILAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 332 THAILAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 333 THAILAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 334 THAILAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 335 THAILAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 336 THAILAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 337 THAILAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 338 THAILAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 339 THAILAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 340 THAILAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 341 INDONESIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 342 INDONESIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 343 INDONESIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 344 INDONESIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 345 INDONESIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 346 INDONESIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 347 INDONESIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 348 INDONESIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 349 INDONESIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 350 INDONESIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 351 INDONESIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 352 INDONESIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 353 INDONESIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 354 INDONESIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 355 INDONESIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 356 INDONESIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 357 INDONESIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 358 INDONESIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 359 INDONESIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 360 INDONESIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 361 INDONESIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 362 INDONESIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 363 INDONESIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 364 INDONESIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 365 INDONESIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 366 INDONESIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 367 INDONESIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 368 INDONESIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 369 INDONESIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 370 INDONESIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 371 INDONESIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 372 INDONESIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 373 INDONESIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 374 MALAYSIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 375 MALAYSIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 376 MALAYSIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 377 MALAYSIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 378 MALAYSIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 379 MALAYSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 380 MALAYSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 381 MALAYSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 382 MALAYSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 383 MALAYSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 384 MALAYSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 385 MALAYSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 386 MALAYSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 387 MALAYSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 388 MALAYSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 389 MALAYSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 390 MALAYSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 391 MALAYSIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 392 MALAYSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 393 MALAYSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 394 MALAYSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 395 MALAYSIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 396 MALAYSIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 397 MALAYSIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 398 MALAYSIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 399 MALAYSIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 400 MALAYSIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 401 MALAYSIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 402 MALAYSIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 403 MALAYSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 404 MALAYSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 405 MALAYSIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 406 MALAYSIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 407 PHILIPPINES DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 408 PHILIPPINES DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 409 PHILIPPINES MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 410 PHILIPPINES DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 411 PHILIPPINES ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 412 PHILIPPINES PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 413 PHILIPPINES PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 414 PHILIPPINES PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 415 PHILIPPINES H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 416 PHILIPPINES H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 417 PHILIPPINES H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 418 PHILIPPINES GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 419 PHILIPPINES GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 420 PHILIPPINES GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 421 PHILIPPINES ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 422 PHILIPPINES ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 423 PHILIPPINES ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 424 PHILIPPINES NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 425 PHILIPPINES PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 426 PHILIPPINES PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 427 PHILIPPINES PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 428 PHILIPPINES DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 429 PHILIPPINES DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 430 PHILIPPINES DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 431 PHILIPPINES ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 432 PHILIPPINES DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 433 PHILIPPINES FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 434 PHILIPPINES MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 435 PHILIPPINES DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 436 PHILIPPINES HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 437 PHILIPPINES HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 438 PHILIPPINES DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 439 PHILIPPINES RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 440 VIETNAM DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 441 VIETNAM DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 442 VIETNAM MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 443 VIETNAM DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 444 VIETNAM ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 445 VIETNAM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 446 VIETNAM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 447 VIETNAM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 448 VIETNAM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 449 VIETNAM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 450 VIETNAM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 451 VIETNAM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 452 VIETNAM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 453 VIETNAM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 454 VIETNAM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 455 VIETNAM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 456 VIETNAM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 457 VIETNAM NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 458 VIETNAM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 459 VIETNAM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 460 VIETNAM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 461 VIETNAM DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 462 VIETNAM DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 463 VIETNAM DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 464 VIETNAM ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 465 VIETNAM DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 466 VIETNAM FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 467 VIETNAM MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 468 VIETNAM DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 469 VIETNAM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 470 VIETNAM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 471 VIETNAM DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 472 VIETNAM RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 473 TAIWAN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 474 TAIWAN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 475 TAIWAN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 476 TAIWAN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 477 TAIWAN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 478 TAIWAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 479 TAIWAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 480 TAIWAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 481 TAIWAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 482 TAIWAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 483 TAIWAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 484 TAIWAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 485 TAIWAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 486 TAIWAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 487 TAIWAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 488 TAIWAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 489 TAIWAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 490 TAIWAN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 491 TAIWAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 492 TAIWAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 493 TAIWAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 494 TAIWAN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 495 TAIWAN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 496 TAIWAN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 497 TAIWAN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 498 TAIWAN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 499 TAIWAN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 500 TAIWAN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 501 TAIWAN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 502 TAIWAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 503 TAIWAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 504 TAIWAN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 505 TAIWAN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 506 REST OF ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
List of Figure
FIGURE 1 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: ASIA-PACIFIC VS. REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 8 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID
FIGURE 11 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET
FIGURE 15 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, 2022
FIGURE 16 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 17 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022
FIGURE 20 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)
FIGURE 22 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022
FIGURE 24 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 25 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 26 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022
FIGURE 28 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)
FIGURE 29 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)
FIGURE 30 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 32 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 33 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 34 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, 2022
FIGURE 36 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 37 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, 2022
FIGURE 40 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 41 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 45 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)
FIGURE 48 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)
FIGURE 49 ASIA-PACIFIC DYSPEPSIA DRUG DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)
FIGURE 52 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
